Replies to post #169559 on Biotech Values

[caravon]

There is another thought:

Both Ph2 in NSCLC and HCC trials employed Tiva in a capsule form. Both Ph3 NSCLC and HCC trials employed Tiva in a tablet form.

There are major efficacy differences between NSCLC Ph2 and Ph3 (Marquee) trial results. Specifically, Tiva in a capsule-form was active in Ph2 KRAS-mutant pts but Tiva in a tablet-form was NOT active in Ph3 KRAS-mutant pts. Why? Was it due to a Tiva delivery formulation?

PS
Few months ago, CLVS has changed their CO-1686 formulation from capsules to tablets. After doing so, CLVS is repeating their Ph1 CO-1686 clinical trial using capsules with CO-1686 tablet-formulation.